# US 8,785,373 B2 · Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,373 B2
- Document ID: US8785373B2
- Status: Granted
- Kind: B2
- Application number: 13/366,390
- Filed: 2012-02-06
- Published: 2012-05-24
- Granted: 2014-07-22
- Earliest claimed: 2004-07-12
- Assignees: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Applicants: Nicola J. Mabjeesh
- Inventors: Nicola J. Mabjeesh
- Web page: https://patentgrep.com/patent/US8785373B2

## CPC

- A61K 38/1709: {from mammals}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/82: Translation products from oncogenes
- C07K 16/18: against material from animals or humans
- C07K 16/30: from tumour cells
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence of such a protein complex.

## Claims

### Claim 1

A method of treating prostate cancer and/or inhibiting a growth of a prostate cancerous tumor and/or prostate cancerous metastases in an individual in need thereof comprising providing to the individual an MSF-A derived peptide or peptide analogue, of up to 30 amino acid resides in length, which includes the amino acid sequence set forth in SEQ ID NO: 4213, thereby treating the prostate cancer and/or inhibiting the growth of the prostate cancerous tumor and/or the prostate cancerous metastases in the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein said MSF-A derived peptide or peptide analogue further comprises a modification of said peptide or peptide analogue for increasing penetration into cells or increasing stability while in a body.

### Claim 3 (depends on 2)

The method of claim 2, wherein said modification comprises an N terminus modification, a C terminus modification, a peptide bond modification, a backbone modification or a residue modification.